Theriva Biologics announces FDA granted RPPD for VCN-01

Theriva Biologics announced that the U.S. Food and Drug Administration, FDA, granted Rare Pediatric Drug Designation, RPPD, for VCN-01 for the treatment of retinoblastoma. VCN-01, Theriva’s lead product candidate, is a systemic, selective, stroma-degrading oncolytic adenovirus. Previously, the FDA granted orphan drug designation to VCN-01 for treatment of retinoblastoma.